Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies.
about
Drugs in development: bisphosphonates and metalloproteinase inhibitorsMetalloproteinases: role in breast carcinogenesis, invasion and metastasisPolycystic liver diseases: advanced insights into the molecular mechanismsCoordinate regulation of IL-1beta and MMP-13 in rat tendons following subrupture fatigue damagePre-Treatment of platinum resistant ovarian cancer cells with an MMP-9/MMP-2 inhibitor prior to cisplatin enhances cytotoxicity as determined by high content screeningA double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer.Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen.Matrix metalloproteinase inhibitor batimastat alleviates pathology and improves skeletal muscle function in dystrophin-deficient mdx mice.Matrix metalloproteinase inhibitors in rheumatic diseases.Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseasesHigh abundance synovial fluid proteome: distinct profiles in health and osteoarthritis.A matrix metalloproteinase inhibitor to treat unresectable cholangiocarcinomaFeasibility of measuring prostate perfusion with arterial spin labelingDevelopment of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study.Inhibition of tumour growth by marimastat in a human xenograft model of gastric cancer: relationship with levels of circulating CEAMarimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial.A phase I and pharmacological study of the matrix metalloproteinase inhibitor BB-3644 in patients with solid tumours.EGF-receptor regulation of matrix metalloproteinases in epithelial ovarian carcinoma.Roles of matrix metalloproteinases and their natural inhibitors in prostate cancer progression.Therapeutic potential of matrix metalloproteinases in Duchenne muscular dystrophy.Intracellular maturation and localization of the tumour necrosis factor alpha convertase (TACE)Isolation and Identification of Two Phenolic Compounds from a Moderately Cytotoxic Fraction of Cousinia verbascifolia Bunge.Matrix metalloproteinases in gastrointestinal cancer.Matrix metalloproteinase inhibitor, marimastat, decreases peritoneal spread of gastric carcinoma in nude mice.Prognostic significance of matrix metalloproteinase-7 (MMP-7) expression at the invasive front in gastric carcinoma.Effect of combination therapy with matrix metalloproteinase inhibitor MMI-166 and mitomycin C on the growth and liver metastasis of human colon cancer.
P2860
Q24795847-6E4FE482-8BDB-41CB-A7AC-5C6444D3CBC1Q24803225-F7EAED64-C377-472B-B520-98255B840FE2Q27001174-6F8766C7-401D-4410-ACB7-150441666468Q28385174-CD0A1C0E-AA11-4AC9-A312-951CAB07E56DQ28394124-BDC9055A-3537-4524-98B3-6320E5E73C93Q30438645-1C9A8570-0CE1-40EB-AA2D-5875C3984460Q33177387-030A0CD0-7739-43CE-80F0-25EEB7E2B94BQ33947243-A7817EDD-FBA3-4D73-A9BB-6CC38408A3BFQ34560579-7620B3CA-7496-4CFA-A59D-EC2B99CABD98Q35185224-CE8B3EB8-5E00-40CD-A824-5362EFBE400AQ35869021-6D2FA35A-17C0-4A32-B19C-002D05AF43F1Q36094601-31955164-627E-4993-BEFF-7C912493372AQ36269104-A545CBBF-6BAD-4B10-B1C1-3B25AB62C141Q36401915-ADEB01F3-7DA3-4F40-B23C-AF5D97A86DF4Q36641139-AE10710A-1B0E-4CD0-915D-F7C4CED3FFA0Q36644664-87C9365C-3297-4EED-937C-41633D297274Q36696731-7DF64464-EB0D-49AF-BAC1-7F2C28CCB399Q37260078-E3EEAF55-3289-4CE1-9E40-21E75050A0BFQ38224605-23DAFCC1-75AE-44D8-B565-CA4E158D5ED7Q38264461-A41483C3-275A-4D1E-B72D-D82E584EBCDAQ40892360-E72E7AE3-A2AD-49EF-BD8A-6903FA405561Q41815549-17B9BE8B-A8A2-4178-80AD-364E2FEB85B8Q41957800-CBC4779E-4B5F-42F7-928D-743E95F47FA3Q44083594-6601BAC3-995A-4220-B17D-1EBC7EFFA3DAQ55222336-2EFBABD9-2F7F-4791-8076-4A8EB3D842EBQ55315506-DE74F69E-9646-4321-AF20-2AD786F0FC56
P2860
Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Combined analysis of studies o ...... dose for longer-term studies.
@en
Combined analysis of studies o ...... dose for longer-term studies.
@nl
type
label
Combined analysis of studies o ...... dose for longer-term studies.
@en
Combined analysis of studies o ...... dose for longer-term studies.
@nl
prefLabel
Combined analysis of studies o ...... dose for longer-term studies.
@en
Combined analysis of studies o ...... dose for longer-term studies.
@nl
P2093
P1476
Combined analysis of studies o ...... dose for longer-term studies.
@en
P2093
Berrington A
Malfetano J
Nemunaitis J
P304
P407
P577
1998-05-01T00:00:00Z